US Bancorp DE Sells 27,216 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

US Bancorp DE reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,095,320 shares of the biopharmaceutical company’s stock after selling 27,216 shares during the quarter. US Bancorp DE owned about 0.09% of Gilead Sciences worth $101,175,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Swedbank AB raised its position in shares of Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after acquiring an additional 189,622 shares in the last quarter. Stephens Inc. AR increased its holdings in Gilead Sciences by 4.3% in the third quarter. Stephens Inc. AR now owns 38,282 shares of the biopharmaceutical company’s stock worth $3,210,000 after purchasing an additional 1,574 shares in the last quarter. Creative Financial Designs Inc. ADV lifted its stake in Gilead Sciences by 7.4% in the third quarter. Creative Financial Designs Inc. ADV now owns 2,740 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 189 shares during the period. Affinity Investment Advisors LLC boosted its holdings in shares of Gilead Sciences by 2.0% during the 3rd quarter. Affinity Investment Advisors LLC now owns 19,974 shares of the biopharmaceutical company’s stock worth $1,675,000 after buying an additional 385 shares in the last quarter. Finally, Roanoke Asset Management Corp NY grew its position in shares of Gilead Sciences by 1.4% during the 3rd quarter. Roanoke Asset Management Corp NY now owns 34,561 shares of the biopharmaceutical company’s stock worth $2,898,000 after buying an additional 462 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the transaction, the chief financial officer now owns 169,061 shares in the company, valued at approximately $17,597,559.49. This represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 293,356 shares of company stock valued at $29,166,240 in the last three months. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $114.31 on Friday. The business’s fifty day simple moving average is $97.42 and its 200 day simple moving average is $90.05. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $114.77. The firm has a market capitalization of $142.46 billion, a P/E ratio of 308.95, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.76%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is presently 854.05%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Morgan Stanley boosted their target price on shares of Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Barclays upped their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Finally, BMO Capital Markets raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.